On the in Vivo Photochemical Rate Parameters for PDT Reactive Oxygen Species Modeling

Overview

Journal Phys Med Biol

Publisher IOP Publishing

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2017 Feb 7

PMID 28166056

Citations 28

Authors

Michele M Kim

Ashwini A Ghogare

Alexander Greer

Timothy C Zhu

Affiliations

Soon will be listed here.

Abstract

Photosensitizer photochemical parameters are crucial data in accurate dosimetry for photodynamic therapy (PDT) based on photochemical modeling. Progress has been made in the last few decades in determining the photochemical properties of commonly used photosensitizers (PS), but mostly in solution or in vitro. Recent developments allow for the estimation of some of these photochemical parameters in vivo. This review will cover the currently available in vivo photochemical properties of photosensitizers as well as the techniques for measuring those parameters. Furthermore, photochemical parameters that are independent of environmental factors or are universal for different photosensitizers will be examined. Most photosensitizers discussed in this review are of the type II (singlet oxygen) photooxidation category, although type I photosensitizers that involve other reactive oxygen species (ROS) will be discussed as well. The compilation of these parameters will be essential for ROS modeling of PDT.

Citing Articles

Modeling synergy and individual effects of X-ray induced photodynamic therapy components.

Hossein F, Naghavi N, Sazgarnia A, Noghreiyan A Sci Rep. 2025; 15(1):453.

PMID: 39748114 PMC: 11696517. DOI: 10.1038/s41598-024-84766-6.

Current State of Melanoma Therapy and Next Steps: Battling Therapeutic Resistance.

Fateeva A, Eddy K, Chen S Cancers (Basel). 2024; 16(8).

PMID: 38672652 PMC: 11049326. DOI: 10.3390/cancers16081571.

A physicochemical model of X-ray induced photodynamic therapy (X-PDT) with an emphasis on tissue oxygen concentration and oxygenation.

Hosseini F, Naghavi N, Sazgarnia A Sci Rep. 2023; 13(1):17882.

PMID: 37857727 PMC: 10587104. DOI: 10.1038/s41598-023-44734-y.

Enhancing the sensitization of neuroblastoma to radiotherapy by the construction of a dual-channel parallel free radicals nanoamplifier.

Zhang W, Li X, Zeng J, Wen X, Zhang C, Zhang Y Mater Today Bio. 2023; 23:100828.

PMID: 37822451 PMC: 10562674. DOI: 10.1016/j.mtbio.2023.100828.

Local monitoring of photosensitizer transient states provides feedback for enhanced efficiency and targeting selectivity in photodynamic therapy.

Sandberg E, Srambickal C, Piguet J, Liu H, Widengren J Sci Rep. 2023; 13(1):16829.

PMID: 37803073 PMC: 10558575. DOI: 10.1038/s41598-023-43625-6.

References

Momma T, Hamblin M, Wu H, Hasan T . Photodynamic therapy of orthotopic prostate cancer with benzoporphyrin derivative: local control and distant metastasis. Cancer Res. 1998; 58(23):5425-31. View

Penjweini R, Liu B, Kim M, Zhu T . Explicit dosimetry for 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a-mediated photodynamic therapy: macroscopic singlet oxygen modeling. J Biomed Opt. 2016; 20(12):128003. PMC: 4698734. DOI: 10.1117/1.JBO.20.12.128003. View

Jarvi M, Niedre M, Patterson M, Wilson B . The influence of oxygen depletion and photosensitizer triplet-state dynamics during photodynamic therapy on accurate singlet oxygen luminescence monitoring and analysis of treatment dose response. Photochem Photobiol. 2010; 87(1):223-34. DOI: 10.1111/j.1751-1097.2010.00851.x. View

Jensen R, Arnbjerg J, Ogilby P . Temperature effects on the solvent-dependent deactivation of singlet oxygen. J Am Chem Soc. 2010; 132(23):8098-105. DOI: 10.1021/ja101753n. View

Finlay J, Zhu T, Dimofte A, Stripp D, Malkowicz S, Busch T . Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy. Photochem Photobiol. 2006; 82(5):1270-8. PMC: 4475578. DOI: 10.1562/2005-10-04-RA-711. View

Zhao B, Yin J, Bilski P, Chignell C, Roberts J, He Y . Enhanced photodynamic efficacy towards melanoma cells by encapsulation of Pc4 in silica nanoparticles. Toxicol Appl Pharmacol. 2009; 241(2):163-72. PMC: 2783992. DOI: 10.1016/j.taap.2009.08.010. View

Kim S, Ohulchanskyy T, Pudavar H, Pandey R, Prasad P . Organically modified silica nanoparticles co-encapsulating photosensitizing drug and aggregation-enhanced two-photon absorbing fluorescent dye aggregates for two-photon photodynamic therapy. J Am Chem Soc. 2007; 129(9):2669-75. PMC: 2556058. DOI: 10.1021/ja0680257. View

Dysart J, Singh G, Patterson M . Calculation of singlet oxygen dose from photosensitizer fluorescence and photobleaching during mTHPC photodynamic therapy of MLL cells. Photochem Photobiol. 2004; 81(1):196-205. DOI: 10.1562/2004-07-23-RA-244. View

Kress M, Meier T, Steiner R, Dolp F, Erdmann R, Ortmann U . Time-resolved microspectrofluorometry and fluorescence lifetime imaging of photosensitizers using picosecond pulsed diode lasers in laser scanning microscopes. J Biomed Opt. 2003; 8(1):26-32. DOI: 10.1117/1.1528595. View

10.

Sterenborg H, van Gemert M . Photodynamic therapy with pulsed light sources: a theoretical analysis. Phys Med Biol. 1996; 41(5):835-49. DOI: 10.1088/0031-9155/41/5/002. View

11.

McDonagh A . Phototherapy: from ancient Egypt to the new millennium. J Perinatol. 2002; 21 Suppl 1:S7-S12. DOI: 10.1038/sj.jp.7210625. View

12.

BONNETT R, Lambert C, Land E, Scourides P, SINCLAIR R, Truscott T . The triplet and radical species of haematoporphyrin and some of its derivatives. Photochem Photobiol. 1983; 38(1):1-8. DOI: 10.1111/j.1751-1097.1983.tb08358.x. View

13.

Bellnier D, Greco W, Loewen G, Nava H, Oseroff A, Pandey R . Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients. Cancer Res. 2003; 63(8):1806-13. View

14.

Zhu T, Finlay J, Hahn S . Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. J Photochem Photobiol B. 2005; 79(3):231-41. PMC: 4470428. DOI: 10.1016/j.jphotobiol.2004.09.013. View

15.

Lustig R, Vogl T, Fromm D, Cuenca R, Hsi R, DCruz A . A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors. Cancer. 2003; 98(8):1767-71. DOI: 10.1002/cncr.11708. View

16.

Weersink R, Forbes J, Bisland S, Trachtenberg J, Elhilali M, Brun P . Assessment of cutaneous photosensitivity of TOOKAD (WST09) in preclinical animal models and in patients. Photochem Photobiol. 2004; 81(1):106-13. DOI: 10.1562/2004-05-31-RA-182. View

17.

Mazor O, Brandis A, Plaks V, Neumark E, Rosenbach-Belkin V, Salomon Y . WST11, a novel water-soluble bacteriochlorophyll derivative; cellular uptake, pharmacokinetics, biodistribution and vascular-targeted photodynamic activity using melanoma tumors as a model. Photochem Photobiol. 2004; 81(2):342-51. DOI: 10.1562/2004-06-14-RA-199. View

18.

Georgakoudi I, Nichols M, Foster T . The mechanism of Photofrin photobleaching and its consequences for photodynamic dosimetry. Photochem Photobiol. 1997; 65(1):135-44. DOI: 10.1111/j.1751-1097.1997.tb01889.x. View

19.

Foster T, Murant R, Bryant R, Knox R, Gibson S, HILF R . Oxygen consumption and diffusion effects in photodynamic therapy. Radiat Res. 1991; 126(3):296-303. DOI: 10.2307/3577919. View

20.

Shonat R, Kight A . Oxygen tension imaging in the mouse retina. Ann Biomed Eng. 2003; 31(9):1084-96. DOI: 10.1114/1.1603256. View